Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH AD-1
2025-524925-42-00Phase 3Authorised
- Sponsor
- Nektar Therapeutics
- Start
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Rezpegaldesleukin monotherapy with Placebo (2 arms). Primary endpoints: IGA 0/1 response at Week 24 and EASI-75 response at Week 24. Planned start Nov 2026; status: authorised.
02
Drugs
rezpegaldesleukin
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2025-524925-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524925-42-00.